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as a Therapeutic Target
Rationale and Clinical Implications*Anand Rohatgi, MD, MSCS,y Scott M. Grundy, MD, PHDzT he majority of efforts to halt atherosclerosishave been focused on limiting cholesterolinﬂux into resident macrophages within the
arterial wall by reducing circulating levels of athero-
genic lipoproteins, which are collectively reﬂected by
non–high-density lipoprotein cholesterol (non–HDL-C)
levels. This strategy has been remarkably effective
in reducing the incidence of atherosclerotic cardiovas-
cular disease (ASCVD) in both primary and secon-
dary prevention populations, largely through lifestyle
modiﬁcation and use of statin pharmacotherapies.
However, reverse cholesterol transport, which is
the movement of cholesterol from tissues to the liver
and out of the body, is also an important mechanism
for maintaining cellular homeostasis. Cholesterol
efﬂux from macrophages is the ﬁrst critical step of
reverse cholesterol transport in the arterial wall. Pre-
clinical and limited human clinical studies support
the concept that improving cholesterol efﬂux pro-
motes plaque regression, shifts macrophages from
pro-inﬂammatory to anti-inﬂammatory states, pro-
motes egress of lipid-laden macrophages out of
the arterial wall, and reduces atherosclerotic lesion
size (1). HDL is the key mediator of cholesterol efﬂux*Editorials published in the Journal of the American College of Cardiology
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has been incorrectly assumed that the cholesterol
load carried by HDL, as reﬂected by HDL-C, also rep-
resents the dynamic efﬂux function of HDL particles.
However, recent studies in humans have revealed
that cholesterol efﬂux capacity is a much more robust
risk marker for incident ASCVD than HDL-C and
cannot be predicted by HDL-C levels. This may
explain the failure of therapies that raised HDL-C
quantity without improving HDL function.
Cholesterol efﬂux capacity assesses the movement
of labeled cholesterol from standardized cells in cul-
ture to serum depleted of apolipoprotein B, making it
more speciﬁc for HDL-mediated efﬂux (2). Efﬂux ca-
pacity in 2 large Caucasian American cohorts (w1,400
participants) (3,4) and a smaller Japanese cohort (w250
participants) (5) demonstrated an inverse association
with prevalent coronary disease. In contrast to these
studies, efﬂux in another cohort of approximately
1,200 Caucasian Americans showed no adjusted asso-
ciation with angiographic coronary stenosis (4). In
addition to cross-sectional observations, several lon-
gitudinal studies assessed efﬂux capacity in both
high- and low-risk individuals. Measurement of efﬂux
capacity in convenience samples using angiographic
cohorts yielded conﬂicting results; 1 in Caucasian
Americans found a positive association with incident
ASCVD events (4), and another in Caucasian Europeans
found an inverse association with cardiovascular
death (6). In contrast, 2 large population-based studies
of participants at low ASCVD risk (multiethnic Ameri-
cans [7] and Caucasian Europeans [8]) yielded consis-
tent inverse associations between baseline cholesterol
efﬂux capacity and incident ASCVD events, which
were adjusted for HDL-C and HDL particle concentra-
tions. Taken together, the relationship between efﬂux
capacity and clinically evident coronary disease
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2212remains mixed among high-risk individuals, but is
thus far consistent and inverse among low-risk pop-
ulations, independent of HDL composition.
Several intriguing observations from these studies
deserve comment. HDL-C levels appear to explain only
approximately 20% to 25% of the variation in efﬂux
capacity, suggesting that the cholesterol load of HDL
particles does not fully reﬂect the efﬂux functionality
of HDL particles. In addition, efﬂux in these studies
quantiﬁed total macrophage efﬂux through various
cholesterol transporters, 30% to 40% of which is
speciﬁc to adenosine triphosphate–binding cassette
transporter A1 (ABCA1) (3). The ABCA1 transporter is
essential to the maturation of HDL from small, dense
particles containing mostly protein (apolipoprotein
A-I) to larger spherical lipoproteins containing more
cholesteryl ester. In contrast, non-ABCA1 transporters
play a signiﬁcant role in efﬂux to larger mature HDL
particles, resulting in high correlations with circulating
HDL-C levels. Efﬂux via ABCA1 is promoted by lipid-
poor apolipoprotein A-I, which is often termed as a
“pre–beta-1” particle, and is correlated poorly with
HDL-C levels (9). Intriguingly, impaired ABCA1-speciﬁc
efﬂux in animal studies consistently leads to increased
atherosclerosis, whereas impaired non-ABCA1 efﬂux
pathways do not (10). In support of these observations,
our recent population-based study used an assay more
speciﬁc for ABCA1 efﬂux than previously used
methods, and we found almost no correlation between
efﬂux and HDL-C levels. However, there were striking
inverse associations with incident ASCVD (7).SEE PAGE 2201Therefore, the study by Nicholls et al. (11), in this
issue of the Journal, which assesses the impact of
cholesteryl ester transport protein (CETP) inhibition
on ABCA1- and non–ABCA1-speciﬁc cholesterol efﬂux
sheds new light on the complexities of HDL meta-
bolism. CETP inhibition causes an accumulation of
large HDL particles loaded with cholesteryl ester,
which markedly increases HDL-C levels. Studies of
CETP inhibition in humans to date have suggested
increases in total cholesterol efﬂux, largely via non-
ABCA1 transporters (12–14). The current study
conﬁrmed these ﬁndings, but also found an increase
in ABCA1-speciﬁc efﬂux and small, dense pre–beta-1
particles with CETP inhibition. Whether these novel
ﬁndings were due to the speciﬁc CETP inhibitor being
tested or differences in risk status across studies (low
risk in the current study vs. high risk in previous
studies) remains unknown. Interestingly, although
pre–beta-1 levels explained 20% to 25% of the varia-
tion in ABCA1-speciﬁc efﬂux at baseline and on
treatment, the change in ABCA1-speciﬁc efﬂux didnot correlate with the change in pre–beta-1 levels
among patients who received only CETP inhibition
treatment, suggesting that much is still unknown
about what governs variation in ABCA1-speciﬁc
efﬂux. The mechanism by which CETP inhibition
would increase ABCA1-speciﬁc efﬂux is unclear, but
these observations highlight the complexity of HDL
function and suggest that therapies that differentially
affect macrophage efﬂux transporters may produce
differential clinical outcomes.
The clinical relevance of manipulating the reverse
cholesterol transport pathway in humans remains
unknown. The failure of niacin and 2 CETP inhibitors to
improve cardiovascular outcomes in addition to
statins, despite increases in HDL-C, certainly dispels
change in HDL-C as a valid sole therapeutic target, but
it also leaves unanswered whether changes in efﬂux
can affect outcomes. These failed therapies increased
total efﬂux, but none increased ABCA1-speciﬁc efﬂux;
therefore, the current CETP inhibitor tested in the
current study might provide a more direct answer in
ongoing outcomes trials. However, it will remain
challenging to fully assess the therapeutic impact of
targeting ABCA1-speciﬁc efﬂux in studies with
concomitant statin use, which may dampen increases
in efﬂux as the current investigation suggests, and in
studies that test therapies like CETP inhibitors that not
only affect HDL but also lower non–HDL-C levels.
Questions that remain include what amount of change
in ABCA1-speciﬁc efﬂux is necessary to confer clinical
beneﬁt, whether the mechanism by which a therapy
changes ABCA1-speciﬁc efﬂux matters, and whether
altering efﬂux will affect plaque stability and plaque
regression similarly across the continuum of plaque
morphology from nascent fatty streaks to calciﬁed
ﬁbrotic plaques to lipid-laden inﬂammatory lesions.
In summary, measuring the dynamic functionality
(efﬂux) versus simply the cholesterol load (HDL-C) of
HDL particles imparts signiﬁcantly more information
about HDL metabolism. The key antiatherosclerotic
function of HDL is to promote cholesterol efﬂux and
reverse cholesterol transport, and this function has
been inversely associatedwith ASCVD in both low- and
high-risk cohorts, independent of HDL-C levels.
Future studies will need to ascertain the determinants
of ABCA1-speciﬁc cholesterol efﬂux, whether targeting
ABCA1-speciﬁc cholesterol efﬂux will promote plaque
regression and improve clinical outcomes, and if dis-
ease and treatment status modify these relationships.
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